多元化治疗对首发精神分裂症患者疗效及认知功能改善的对照研究

目的探讨多元化治疗对首发精神分裂症患者疗效及认知功能改善的效果。方法将80例首发精神分裂症患者随机分为研究组40例（接受多元化治疗）和对照组40例（仅接受药物治疗），共干预12周。在基线及治疗后第12周末分别进行阳性和阴性综合征量表（PANSS）、韦氏成人智力量表（WAIS．RC）、韦氏记忆量表（WMS）、威斯康星卡片分类测验（WCST）及治疗中需处理的不良反应症状量表（TESS）测定以评定疗效及不良反应。结果治疗后第12周末研究组PANSS总分、WCST的总测验数、持续错误数、随机错误数评分显著低于对照组（P〈0．05，P〈0．01），WAIS—RC的语言智商量表、操作智商量表、总智商量表、WMS总分评分显著高于对照组（P〈0．05，P〈0．01）。两组TESS评分差异无统计学意义（P〉0．05）。结论多元化治疗可明显改善首发精神分裂症患者的精神症状及认知功能，安全性较高。

A comparative study of multivariant therapy to improve symptoms and cognitive function in patients with first -episode schizophrenia.

Objective To explore the effect of muhivariant therapy on improving clinical symptoms and cognitive function of patients with first-episode schizophrenia. Methods A total of 80 patients with first-episode schizophrenia were randomly divided into study group （40 cases ） treated with multivariant therapy and control group （40 cases ） treated with simple pharmacotherapy for 12 weeks, All patients were assessed with Positive and Negative Syndrome Scale （PANSS）, Weehsler Adult Intelligence Scale-Revised by China （WAIS-RC）, Wechsler Memory Scale （WMS）, Wisconsin Card Sorting Test （WCST） and Treatment Emergent Symptom Scale （TESS） at baseline and at the end of the 12-week treatment to evaluate the efficiency and the side effects. Results At the end of the 12-week treatment, total trials of category, perseverative errors and nonperseverative errors in WAIS-RC and total score of PANSS in study group were significantly lower than those in control group （ P 〈 0.05 or P 〈 0.01 ） Verbal IQ, performance IQ, full IQ of WAIS-RC and total score of WMS in study group were significantly higher than those in control group （ P 〈 0. 05 ）. There was no significant difference in score of TESS between the two groups （ P 〉 0.05 or P 〈 0.01 ）. Conclusion Muhivariant therapy can effectively improve the clinical symptoms and cognitive function in patients with first-episode schizophrenia.